病理性多動症と心臓のインタースティチウム. 線維症とレニン-アニオテンシン-アルドステロン系
1Division of Cardiology, University of Missouri-Columbia, Columbia 65212.
Circulation
|June 1, 1991
まとめ
左心室多動症 (LVH) は心不全につながる可能性があります. 心臓の線維芽細胞によって引き起こされ,高血圧とアルドステロンの影響を受けて発症する線維症は,心筋硬化と機能不全を引き起こし,新たな治療目標を示唆する.
科学分野:
- 心臓病学 心臓病学
- 病理学 パトロジー
- バイオケミストリー バイオケミストリー
背景:
- 左心室縮症 (LVH) は,心筋不全の主要な危険因子である.
- LVH誘発の心臓機能不全の基礎となる病理学的メカニズムは完全に理解されていません.
- 心筋組織構造の異常,特に線維症は,心機能障害に寄与する.
研究 の 目的:
- 病理的なLVHの発症における非肌細胞細胞,特に心筋線維芽細胞の役割を調査する.
- LVHの文脈でミオサイトと非ミオサイト細胞の成長の関係を明らかにする.
- 高血圧の心臓におけるインタースティシャルおよび周血管繊維症に寄与する要因を特定する.
主な方法:
- 動物モデルでの実験的高血圧のインビボ研究で使用された.
- アンジオテンシンIIとアルドステロンの血濃度の変動による影響を調査した.
- 筋動脈の構造と線維症を評価するために,形態測定と形態学的分析を使用した.
主要な成果:
- 実験的高血圧におけるミオサイトと非ミオサイト細胞の独立した成長が実証された.
- ハイパルトロフィ化した心室における線維性コラーゲンの異常な蓄積 (線維症) が確認されました.
- 動脈高血圧とアルドステロンの値上昇は,心筋線維芽細胞の活性化と心筋の構造的異質性に関連していることが判明しました.
結論:
- 非筋細胞細胞,特に心筋線維芽細胞は,病理的なLVHの決定的な決定因子です.
- 冠動脈 perfusion 圧力の上昇とアルドステロンは,心筋線維症と心室機能障害に寄与します.
- 線維芽細胞の反応メカニズムに関するさらなる研究は,病理的なLVHを予防し,逆転させるための戦略を開発するために必要です.
関連する概念動画
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...


